Overview

Estimation of Off-Label Use of XGEVA® (Denosumab) Using Population-Based Databases in Denmark

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate off-label XGEVA use in Denmark using data linked from registries and other sources in Northern Jutland Region and Copenhagen. This will allow for accurate assessment of prescriptions and diagnoses, especially those related to cancer patients during the first year post the initial market availability of XGEVA.
Details
Lead Sponsor:
Amgen
Collaborator:
University of Aarhus
Treatments:
Denosumab